Related Experiment Video
Updated: Jul 8, 2026
14:35
Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs
Published on: April 17, 2021
[Beta blockade in acute myocardial infarction]
Srpski Arhiv Za Celokupno Lekarstvo
|June 1, 1992
Summary
Early intravenous beta-blocker treatment for myocardial infarction (MI) significantly reduces chest pain, infarct size, and arrhythmias. This intervention also lowers the risk of cardiac arrest, reinfarction, and overall mortality by 13%.
Area of Science:
- Cardiology
- Pharmacology
Context:
- Myocardial infarction (MI) is a leading cause of mortality and morbidity worldwide.
- Timely intervention is crucial for improving patient outcomes following acute MI.
Purpose:
- To review randomized studies on the efficacy of intravenous beta-blocker administration in acute myocardial infarction.
- To assess the impact of early beta-blocker therapy on clinical outcomes and mortality.
Summary:
- Intravenous beta-blockade initiated within 12 hours (preferably 6) of chest pain onset, followed by oral administration, leads to significant benefits.
- Key findings include reduced chest pain, limited infarct size, decreased ventricular arrhythmias, and fewer instances of cardiac arrest and reinfarction.
- Pooled analysis of 14 trials demonstrated a 13.0% overall reduction in mortality for patients receiving beta-blockers compared to controls.
Impact:
- Early beta-blocker therapy is a safe and well-tolerated intervention for approximately 50% of eligible myocardial infarction patients.
- This treatment strategy offers substantial improvements in survival rates and reduces the incidence of major adverse cardiac events.
Related Concept Videos
01:28Acute Coronary Syndrome IV: Interprofessional Care
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
01:30Acute Coronary Syndrome I: Introduction
Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
01:30Acute Coronary Syndrome III: Diagnostic Studies
Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
01:22Heart Failure Drugs: β-Blockers
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
01:19Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
01:28Antihypertensive Drugs: Types of β-Blockers
β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and vasodilation. This widens airways and...